Improved Overall Survival in Patients Developing Endocrine Toxicity During Treatment with Nivolumab for Advanced Non-small Cell Lung Cancer in a Prospective Study

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2024 Apr 29

PMID 38683497

Authors

M Albertelli

G Rossi

E Nazzari

C Genova

F Biello

E Rijavec

M G Dal Bello

L Patti

M Tagliamento

G Barletta

P Morabito

M Boschetti

A Dotto

D Campana

D Ferone

F Grossi

Affiliations

Soon will be listed here.

Abstract

Purpose: Immune checkpoint inhibitors (ICPIs) disrupting PD-1/PD-L1 axis have revolutionized the management of advanced non-small cell lung cancer (NSCLC). Some studies identified the development of endocrine toxicity as predictor of better survival in cancer patients treated with ICPIs. The aim of study was to evaluate survival and new onset of immune-related endocrine adverse events (irAEs) in patients treated with nivolumab for advanced NSCLC.

Methods: In a prospective study, 73 patients with previously treated advanced NSCLC received nivolumab in monotherapy. Blood samples were collected at each cycle to monitor thyroid autoimmunity, thyroid, adrenal and somatotroph axes, while thyroid morphology was evaluated by ultrasonography.

Results: An impaired thyroid function was recorded in 23.4% of patients (n = 15). Eight patients developed asymptomatic transient thyrotoxicosis (ATT) evolving to hypothyroidism in 50% of cases. In addition, seven patients developed overt hypothyroidism without ATT and with negative autoantibodies. Patients who developed hypothyroidism proved to have better overall survival (OS) as compared with non-developers at both univariate (p = 0.021) and multivariate analyses (p = 0.023). The survival curve of patients with reduced IGF-I at baseline, or displaying its reduction during the follow-up, showed significantly reduced median survival compared to patients with normal/high IGF-I levels (p = 0.031).

Conclusions: Thyroid function abnormalities are the major irAEs in patients treated with nivolumab, and hypothyroidism onset is associated with prolonged survival. Our findings indicate that the development of hypothyroidism is a positive predictive biomarker of nivolumab antitumor efficacy in patients with NSCLC. Low IGF-I levels could represent a negative prognostic factor during nivolumab therapy.

References

Cheung Y, Wang W, McGregor B, Hamnvik O . Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022; 71(8):1795-1812. PMC: 9276851. DOI: 10.1007/s00262-021-03128-7. View

de Miguel M, Calvo E . Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell. 2020; 38(3):326-333. DOI: 10.1016/j.ccell.2020.07.004. View

Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S . "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord. 2021; 22(3):615-636. PMC: 8346388. DOI: 10.1007/s11154-021-09647-z. View

Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao M . Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist. 2019; 25(1):64-77. PMC: 6964132. DOI: 10.1634/theoncologist.2019-0027. View

Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Rubino M . Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. J Clin Med. 2021; 10(1). PMC: 7795591. DOI: 10.3390/jcm10010088. View

Di Molfetta S, Dotto A, Fanciulli G, Florio T, Feola T, Colao A . Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?. Front Endocrinol (Lausanne). 2021; 12:667784. PMC: 8081349. DOI: 10.3389/fendo.2021.667784. View

Guo L, Zhang H, Chen B . Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer. 2017; 8(3):410-416. PMC: 5332892. DOI: 10.7150/jca.17144. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

10.

Barroso-Sousa R, Barry W, Garrido-Castro A, Hodi F, Min L, Krop I . Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2017; 4(2):173-182. PMC: 5838579. DOI: 10.1001/jamaoncol.2017.3064. View

11.

Osorio J, Ni A, Chaft J, Pollina R, Kasler M, Stephens D . Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2016; 28(3):583-589. PMC: 5834017. DOI: 10.1093/annonc/mdw640. View

12.

Kotwal A, Kottschade L, Ryder M . PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid. 2019; 30(2):177-184. PMC: 7047075. DOI: 10.1089/thy.2019.0250. View

13.

Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R . Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2017; 4(3):374-378. PMC: 6583041. DOI: 10.1001/jamaoncol.2017.2925. View

14.

Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H . Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019; 19(1):974. PMC: 6805586. DOI: 10.1186/s12885-019-6150-y. View

15.

Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello M, Metro G . Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2018; 145(2):479-485. DOI: 10.1007/s00432-018-2805-3. View

16.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

17.

Maria Corsello S, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F . Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013; 98(4):1361-75. DOI: 10.1210/jc.2012-4075. View

18.

Weber J, Hodi F, Wolchok J, Topalian S, Schadendorf D, Larkin J . Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017; 35(7):785-792. DOI: 10.1200/JCO.2015.66.1389. View

19.

de Velasco G, Je Y, Bosse D, Awad M, Ott P, Moreira R . Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017; 5(4):312-318. PMC: 5418853. DOI: 10.1158/2326-6066.CIR-16-0237. View

20.

Kumar V, Chaudhary N, Garg M, Floudas C, Soni P, Chandra A . Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017; 8:49. PMC: 5296331. DOI: 10.3389/fphar.2017.00049. View